Prof John Seymour
Honorary (Professorial Fellow)
Department of Medicine
1153 Scholarly works
9 Projects
HIGHLIGHTS
2023
Research grants (ARC, NHMRC, MRFF)
PRECISION\2013 Pharmacogenomic Medicines Optimisation for People With Cancer
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752021
Journal article
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
DOI: 10.1182/bloodadvances.20210050832021
Journal article
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
DOI: 10.1182/blood.20200095782020
Research grants (other domestic)
Exercise Oncology Services Closer to Home: Improving Equity of Access and Survivor Outcome S Through the Development of a Multi-Disciplinary Digitally-Delivered Service.
RECENT SCHOLARLY WORKS
2026
Journal article
ROCKET-CLL: A randomized, open-label, multicenter, phase 3 study of rocbrutinib (LP-168) versus pirtobrutinib in covalent BTK inhibitor (cBTKi) in pretreated relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
DOI: 10.1200/jco.2026.44.16_suppl.tps71002026
Journal article
Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management
DOI: 10.1002/ajh.702892026
Journal article
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study
DOI: 10.1002/hem3.703862026
Journal article
Venetoclax retreatment in chronic lymphocytic leukemia is biologically rational and clinically effective
DOI: 10.1182/bloodadvances.20260198712026
Journal article
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
DOI: 10.1016/S2352-3026(26)00037-22026
Journal article
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
DOI: 10.1016/j.radonc.2026.1113882026
Journal article
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia
DOI: 10.1182/blood.20250299052026
Journal article
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma
DOI: 10.1182/bloodadvances.2025016646